MedCath Corporation MDTH
-
Measurement Specialties (MEAS) knocks out a 7.9% gain after S&P adds the company to its MidCap 400 Index. The company it replaces, MedCath ( MDTH ), is down 0.4%.
Measurement Specialties ( MEAS ) knocks out a 7.9% gain after S&P adds the company to its MidCap 400 Index. The company it replaces, MedCath ( MDTH ), is down 0.4% . Post your comment!
-
Dropping Coverage of MedCath
We are dropping coverage of MedCath MDTH to focus our resources elsewhere. We provide broad coverage of numerous companies across a variety of industry groups and adjust our coverage as necessary based on client demand and investor interest.
-
MedCath Poised to Sell Hospital
MedCath MDTH is still pursuing its plan to sell off its hospitals individually, or the entire company as a package. Thus far, the firm has …
-
MedCath Explores Strategic Options
MedCath MDTH continues to diversify its services, in the hopes this will alleviate the firm's heavy dependence on cardiac procedures. We …
-
Maintaining MedCath's Fair Value
We're maintaining our fair value estimate for MedCath MDTH after the company finished its fiscal 2009 slightly below our projections. While the company did not provide its financial outlook …
-
Outpatient Shift Continues for MedCath
MedCath MDTH reported its third-quarter results on Wednesday, and we're leaving our fair value estimate unchanged following the release …
-
Previewing MedCath's 2Q
MedCath MDTH is set to release second-quarter results over the next several days, and we're leaving our fair value estimate unchanged ahead …
-
Positive Legislation for MedCath
On Wednesday, MedCath MDTH released first-quarter results that outpaced our expectations, but we don't expect to change our fair value estimate on the …
-
MedCath under Review
We're placing MedCath MDTH under review following the release of its disappointing fourth-quarter results. Both revenue and profitability failed to meet …
-
MedCath Uncertainty to Very High
We're moving our uncertainty rating for MedCath MDTH to very high from high to account for possible consequences of a prolonged credit crunch. While MedCath is not highly levered …